Role of genetic factors in statins side-effects.

In conclusion, the picture of putative pharmacogenetic modulation of statins safety is reaching a growing body of evidence for translation into clinical practice but more specific studies for each single statin, in different clinical settings, both from genome-wide or competitive candidate genes evaluation, are needed before describing a definitive class-risk profile. PMID: 22524173 [PubMed - indexed for MEDLINE]
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Related Links:

Source: Patient Preference and Adherence - Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Authors: Mühleck F, Laufs U Abstract Coronary artery disease (CAD) is the most frequent cause of morbidity and mortality worldwide. Lifestyle modifications and drug treatment of cardiovascular risk factors are able to effectively prevent CAD. The basis of prevention is the assessment of the individual cardiovascular risk, e.g. by using a validated risk score. Documented evidence for prevention of CAD is available for the control of hypertension using angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB) and calcium antagonists, for the treatment of hypercholesterolemia using ...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
MHRA aware of issue and advises patients to continue to taking their diabetes medicine Related items fromOnMedica People on statins at greater risk of skin infections and diabetes Raised risk of MI and mortality when starting sulfonylurea Use of DPP-4 inhibitors associated with increased risk of IBD Vitamin D does not reduce kidney damage in type 2 diabetes Use pioglitazone only in selected patients, says EMA guidance
Source: OnMedica Latest News - Category: UK Health Source Type: news
ConclusionsThere was a significant association between statin use and TUG inability in older Chinese inpatients with diabetes.
Source: The Journal of Nutrition, Health and Aging - Category: Nutrition Source Type: research
The Pharmacogenomics Journal, Published online: 05 December 2019; doi:10.1038/s41397-019-0125-xStatin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: Source Type: research
AbstractPurpose of ReviewTo describe lipid abnormalities in diabetes, when they occur and the evidence base for lipid management with established and new drugs to prevent diabetes complications. We also discuss how to manage statin intolerance.Recent FindingsStatins remain first-line therapy in patients with diabetes, though newer therapies to reduce LDL-C have emerged, including ezetimibe as an add-on therapy to statins, and injectable PCSK9 inhibitors, both of which are safe and effective in diabetes. Emerging evidence suggests a need to consider lipid-lowering therapies more often in younger patients with both type 1 an...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however re...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
ConclusionsAlthough most high-risk patients with T2D and CV disease were on lipid-lowering therapy, only 1:3 had LDL-C 
Source: American Heart Journal - Category: Cardiology Source Type: research
Neither vitamin D3 nor omega-3 fatty acid supplements cut CKD risk in people with type 2 diabetes over five years Related items fromOnMedica UK research reveals racial inequalities in diabetes care Statins of small and uncertain benefit in primary prevention Should we recognise obesity as a disease? Sugar not saturated fat is the major issue for CVD WHO dietary fat guidance fails to consider crucial evidence
Source: OnMedica Latest News - Category: UK Health Source Type: news
Purpose of review Atherogenic dyslipidaemia, characterized by high plasma triglycerides (a surrogate for triglyceride-rich remnant lipoproteins) and low high-density lipoprotein cholesterol (HDL-C), is prevalent in patients with type 2 diabetes mellitus (T2DM) and contributes to a high modifiable residual cardiovascular risk. Fibrates are effective in managing hypertriglyceridaemia but lack consistent cardiovascular benefit in clinical trials and exhibit pharmacokinetic interaction with statins (gemfibrozil) and renal and hepatic safety issues (fenofibrate). The selective peroxisome proliferator-activated receptor alpha ...
Source: Current Opinion in Lipidology - Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research
More News: Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Genetics | Heart | Hematology | Lipitor | Liver | Pravastatin | Simvastatin | Statin Therapy | Study | Urology & Nephrology | Zivast | Zocor